Skip to main content

Table 1 Patient characteristics

From: Significance of molecular classification of ependymomas: C11orf95-RELA fusion-negative supratentorial ependymomas are a heterogeneous group of tumors

Total number of enrolled patients   107
Male:female ratio   55: 51 (Unknown, 1)
Observation period (median, range)   49 months (0–219)
Age (median, range) 10 years, (0–76 years)  
< 3 22
3–18 42
18< 42
Unknown 1
Extent of resection of the primary tumors Total resection 51
Partial resection/biopsy 47
Unknown 9
Adjuvant therapy for the primary tumors Radiation therapy (RTx) 32
Chemotherapy (CTx) 13
RTx + CTx 22
No adjuvant therapy 29
No data 11
Total number of enrolled samples   113
Tumor locations Supratentorial 38
Posterior fossa 63
Spine 12
Time of surgery for the samples Primary 91
Recurrent 18
Unknown 4
Pathological diagnosis (Institutional diagnosis) Grade 1 2
Grade 2 46
Grade 3 60
No data of grading 5
Pathological diagnosis (Central diagnosis) Grade 1 1
Grade 2 33
Grade 3 67
Other diagnoses 12
Molecular status RELA fusion positive 20
YAP1 fusion positive 1
PFA 45
PFB 15